A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
about
Pharmacological treatment of children with gastro-oesophageal refluxMedical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux diseaseMedical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux diseaseRabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trialNon-pharmacologic treatment strategies in gastroesophageal reflux disease.Management strategies for gastroesophageal reflux disease.Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.Current trends in the management of gastroesophageal reflux disease: a review.A review of rabeprazole in the treatment of acid-related diseasesA randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux diseasePostmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders.Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.
P2860
Q24187847-3EE856F3-640E-4F8D-A88F-6726123A7093Q24240101-CBA41928-C335-4FEE-B085-8A75FC1EDF24Q24245681-860C1764-2366-4B44-BA45-ED2055788B7BQ35010979-A1D41AFA-F70D-4EB4-820F-20FBF76664E9Q35609697-33FC469F-6497-43DE-B5E0-12DE0081E99BQ35678985-81569893-9EC0-4E24-8D93-2F82B95A8BCCQ35868517-58C43830-1C4E-4361-B667-AF18A5EBDD48Q35868522-AFA80057-5C96-4553-A314-BE6F20C0BB7AQ35868527-B33B55F5-3473-4697-BD9A-CE18056A1F95Q35923964-AE30B9DE-EACA-409C-B00A-E6C2F120481BQ36107247-9ED3CB54-4B5A-4BFF-9B97-78F3A245650DQ36661321-720605A6-D71B-49F1-9FAA-750FDB81628AQ36817415-0D465C6C-5483-4866-9FC4-66BD3BEA7A77Q37663478-B6F15C2C-0342-45C0-9C31-FFDF4CC0D13CQ46203790-92079EBC-144D-4E50-BF76-48DB04380CCBQ46642633-7CD1F598-97EF-4B20-82F5-7D0EBE7B48C9Q46889718-0F29BA85-00A6-4F15-997C-9683B887E790
P2860
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A randomized, double-blind tri ...... l reflux disease over 5 years.
@en
A randomized, double-blind tri ...... l reflux disease over 5 years.
@nl
type
label
A randomized, double-blind tri ...... l reflux disease over 5 years.
@en
A randomized, double-blind tri ...... l reflux disease over 5 years.
@nl
prefLabel
A randomized, double-blind tri ...... l reflux disease over 5 years.
@en
A randomized, double-blind tri ...... l reflux disease over 5 years.
@nl
P2093
P2860
P1476
A randomized, double-blind tri ...... l reflux disease over 5 years.
@en
P2093
A Morocutti
B Thjodleifsson
European Rabeprazole Study Group
K D Bardhan
T J Humphries
P2860
P304
P356
10.1046/J.1365-2036.2003.01446.X
P407
P577
2003-02-01T00:00:00Z